Twitter 25 min ago
Botanix Pharmaceuticals Ltd@BotanixPharma
Finish line | Soon, we’re expecting a mid-cycle review meeting with the FDA for our lead product, Sofpironium Bromide - a significant de-risking step on our journey to FDA approval which is on track for Q3 this year. Watch this video to learn more https://bit.ly/BOT_MarketHerald_MidCycle$BOT
Ann: Confirmation Sofpironium Bromide NDA Formally Under Review, page-55
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $689.3M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 37.5¢ | $1.784M | 4.691M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 248028 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 356327 | 6 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |